Study S001532

Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03856047
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 706
Start: 2019-03-01
Primary completion: 2020-03-02
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:NNC0174-0833; DRUG:Placebo (NNC0174-0833); DRUG:Liraglutide 3.0 mg; DRUG:Placebo (Liraglutide 3.0 mg)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1214-0429; REGISTRY:2018-001945-14; NIH:2018

Registered primary outcomes

Change in Body Weight (%) [From baseline (week 0) to week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017871	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lau DCW, Lancet (London, England)	2021	Randomized trial	PMID 34798060 DOI	cites ClinicalTrials.gov:NCT03856047; registry reference RESULT:34798060